Abstract
Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in a variety of tumour types, including lung cancer. Larotrectinib is a highly selective, central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor that demonstrated an objective response rate (ORR) of 87% across 15 independent review committee (IRC)-evaluable patients with TRK fusion lung cancer as of July 2020 (Drilon et al, JCO Precis Oncol 2021). We report data on these patients with longer follow-up and on an expanded dataset of patients with TRK fusion lung cancer treated with larotrectinib.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
